Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Inclusion Criteria: * A male or female between, and including, 42 and 64 days of age at the time of the first vaccination * Written informed consent obtained from parents/legal guardian of the subject * Free of obvious health problems as established by medical history and/or clinical examination before entering the study * Hepatitis B vaccination at birth (within 48 hours) Available for all scheduled study visits Exclusion Criteria: * Use of any investigational drug or any investigational vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up * Planned administration of a vaccine not foreseen by the study protocol * Known or suspected impairment of immune function, known Human immunodeficiency virus (HIV)-positivity, receiving immunosuppressive therapy, or having received systemic immunosuppressive therapy within 1 month prior to study entry (note: inhaled and topical steroids are allowed) * Administration of parenteral immunoglobulin preparation and/or blood products since birth * Previous vaccination against Haemophilus influenzae type b (Hib) and/or diphtheria, tetanus, pertussis (DTP) * History of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component or to products containing mercury compounds, such as sodium ethylmercuro-thiosalicylate * Significant acute infection * Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives * Participation in another clinical study